Hai-Feng Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hai-Feng Zhou has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Wei-Zhong Zhou
Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
6 shared publications - Sheng Liu
Department of Interventional Radiology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, Jiangsu, China
5 shared publications Wei Yang
4 shared publicationsYu Liu
3 shared publicationsBi-Fei Wu
Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, China
2 shared publicationsDi Zhu
2 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Combined TIPS and TACE for patients with hepatocellular carcinoma and variceal bleeding secondary to portal vein tumor thrombus
The study aimed to assess the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) combined with transarterial chemoembolization (TA
- 24 July 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessCombined TIPS and TACE for patients with hepatocellular carcinoma and variceal bleeding secondary to portal vein tumor thrombus
The study aimed to assess the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) combined with transarterial chemoembolization (TA
- Open Access
- 15 January 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 18 (1)
Multimodal clinical parameters-based immune status associated with the prognosis in patients with hepatocellular carcinoma
Hepatocellular carcinoma presents with three distinct immune phenotypes, including immune-desert, immune-excluded, and immune-inflamed, indicating various treatment responses and prognostic outcomes. The clinical application of multi-omics parameters is still restricted by the expensive and less accessible assays, although they accurately reflect immune status. A comprehensive evaluation framework based on “easy-to-obtain” multi-model clinical parameters is urgently required, incorporating clinical features to establish baseline patient profiles and disease staging; routine blood tests assessing systemic metabolic and functional status; immune cell subsets quantifying subcluster dynamics; imaging features delineating tumor morphology, spatial configuration, and perilesional anatomical relationships; immunohistochemical markers positioning qualitative and quantitative detection of tumor antigens from the cellular and molecular level. This integrated phenomic approach aims to improve prognostic stratification and clinical decision-making in hepatocellular carcinoma management conveniently and practically.
- 15 January 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 18 (1)
Open AccessMultimodal clinical parameters-based immune status associated with the prognosis in patients with hepatocellular carcinoma
Hepatocellular carcinoma presents with three distinct immune phenotypes, including immune-desert, immune-excluded, and immune-inflamed, indicating various treatment responses and prognostic outcomes. The clinical application of multi-omics parameters is still restricted by the expensive and less accessible assays, although they accurately reflect immune status. A comprehensive evaluation framework based on “easy-to-obtain” multi-model clinical parameters is urgently required, incorporating clinical features to establish baseline patient profiles and disease staging; routine blood tests assessing systemic metabolic and functional status; immune cell subsets quantifying subcluster dynamics; imaging features delineating tumor morphology, spatial configuration, and perilesional anatomical relationships; immunohistochemical markers positioning qualitative and quantitative detection of tumor antigens from the cellular and molecular level. This integrated phenomic approach aims to improve prognostic stratification and clinical decision-making in hepatocellular carcinoma management conveniently and practically.
- Open Access
- 1 December 2025
- Published by KEAI Publishing in Journal of Interventional Medicine
- Vol. 7 (1) , 3-9
Validation of the CRAFITY score for predicting prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization combined with systemic therapy
- 1 December 2025
- Published by KEAI Publishing in Journal of Interventional Medicine
- Vol. 7 (1) , 3-9
Open AccessValidation of the CRAFITY score for predicting prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization combined with systemic therapy
- Open Access
- 28 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-21
Artificial intelligence-driven pathomics in hepatocellular carcinoma: current developments, challenges and perspectives
Hepatocellular carcinoma (HCC) is a highly malignant tumor with elevated incidence and mortality rates globally. Its complex etiology and pronounced heterogeneity present significant challenges in diagnosis and treatment. Recent advancements in artificial intelligence (AI) have demonstrated transformative potential to usher a new wave of precision oncology. Pathomics, an AI-based digital pathology technique, facilitates the extraction of extensive datasets from whole-slide histopathological images, enabling quantitative analyses to improve diagnosis, treatment, and prognostic prediction for HCC. Furthermore, emerging pathological foundation models are revolutionizing traditional paradigms and providing a robust framework for the development of specialized pathomics models tailored to specific clinical tasks in HCC. Despite its promise, pathomics research in HCC remains in its infancy, with clinical implementation hindered by challenges such as data heterogeneity, model interpretability, ethical concerns, regulatory issues, and the absence of standardized industry protocols. Future initiatives should prioritize the conduction of prospective multi-center studies, the integration of multi-modal data, the enhancement of regulatory frameworks, and the establishment of industry-wide standardized guidelines and compliant platform infrastructures to accelerate the clinical adoption of pathomics for personalized HCC treatment.
- 28 July 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-21
Open AccessArtificial intelligence-driven pathomics in hepatocellular carcinoma: current developments, challenges and perspectives
Hepatocellular carcinoma (HCC) is a highly malignant tumor with elevated incidence and mortality rates globally. Its complex etiology and pronounced heterogeneity present significant challenges in diagnosis and treatment. Recent advancements in artificial intelligence (AI) have demonstrated transformative potential to usher a new wave of precision oncology. Pathomics, an AI-based digital pathology technique, facilitates the extraction of extensive datasets from whole-slide histopathological images, enabling quantitative analyses to improve diagnosis, treatment, and prognostic prediction for HCC. Furthermore, emerging pathological foundation models are revolutionizing traditional paradigms and providing a robust framework for the development of specialized pathomics models tailored to specific clinical tasks in HCC. Despite its promise, pathomics research in HCC remains in its infancy, with clinical implementation hindered by challenges such as data heterogeneity, model interpretability, ethical concerns, regulatory issues, and the absence of standardized industry protocols. Future initiatives should prioritize the conduction of prospective multi-center studies, the integration of multi-modal data, the enhancement of regulatory frameworks, and the establishment of industry-wide standardized guidelines and compliant platform infrastructures to accelerate the clinical adoption of pathomics for personalized HCC treatment.
- Open Access
- 1 February 2025
- Published by AME Publishing Company in Chinese Clinical Oncology
- Vol. 14 (1) , 1
A sub-cluster of cancer cells indicates poor prognosis in advanced hepatocellular carcinoma
Background: For patients with advanced hepatocellular carcinoma (HCC), it is emergent to focus on elucidating different classifications of intratumoral heterogeneity and understanding the mechanisms of treatment resistance to improve prognosis. This study aims to classify the sub-clusters of cancer cells in patients diagnosed with advanced HCC, and identify the genes, pathways and microenvironment associated with prognosis. Methods: Single-cell transcriptomic profiling were conducted on advanced HCC samples. Bulk RNA-seq transcriptome data were obtained from The Cancer Genome Atlas (TCGA) database. Prognosis analysis was performed for survival stratification within the identified sub-clusters. Enriched genes and pathways were determined, and the association and underlying mechanism of the identified sub-cluster of cancer cells were elucidate with other cellular components within advanced HCC tumor tissue. Results: A total of 26,800 cells were obtained from two patients with advanced HCC. Seven sub-clusters were identified, and only the CancerCell 6 cluster were exhibited significant disparities in both overall survival (OS) and progression-free survival (PFS) rates according to the 370 HCC patients from the TCGA database. The CancerCell 6 cluster was associated with adenosine triphosphate (ATP)-related pathways and the high expression of pyruvate kinase M (PKM). It also demonstrated a strong interaction ability with mononuclear phagocytes (MPs). The MPs_MMP9 cluster showed strong interactions between the CancerCell 6 cluster and related signaling pathways of EDN and NOTCH, indicating a tendency toward M2 polarization. Conclusions: This study identified the CancerCell 6 cluster associated with a poor prognosis and characterized by ATP-related metabolism. This cluster demonstrated interactions with MPs inclined to M2 polarization.
- 1 February 2025
- Published by AME Publishing Company in Chinese Clinical Oncology
- Vol. 14 (1) , 1
Open AccessA sub-cluster of cancer cells indicates poor prognosis in advanced hepatocellular carcinoma
Background: For patients with advanced hepatocellular carcinoma (HCC), it is emergent to focus on elucidating different classifications of intratumoral heterogeneity and understanding the mechanisms of treatment resistance to improve prognosis. This study aims to classify the sub-clusters of cancer cells in patients diagnosed with advanced HCC, and identify the genes, pathways and microenvironment associated with prognosis. Methods: Single-cell transcriptomic profiling were conducted on advanced HCC samples. Bulk RNA-seq transcriptome data were obtained from The Cancer Genome Atlas (TCGA) database. Prognosis analysis was performed for survival stratification within the identified sub-clusters. Enriched genes and pathways were determined, and the association and underlying mechanism of the identified sub-cluster of cancer cells were elucidate with other cellular components within advanced HCC tumor tissue. Results: A total of 26,800 cells were obtained from two patients with advanced HCC. Seven sub-clusters were identified, and only the CancerCell 6 cluster were exhibited significant disparities in both overall survival (OS) and progression-free survival (PFS) rates according to the 370 HCC patients from the TCGA database. The CancerCell 6 cluster was associated with adenosine triphosphate (ATP)-related pathways and the high expression of pyruvate kinase M (PKM). It also demonstrated a strong interaction ability with mononuclear phagocytes (MPs). The MPs_MMP9 cluster showed strong interactions between the CancerCell 6 cluster and related signaling pathways of EDN and NOTCH, indicating a tendency toward M2 polarization. Conclusions: This study identified the CancerCell 6 cluster associated with a poor prognosis and characterized by ATP-related metabolism. This cluster demonstrated interactions with MPs inclined to M2 polarization.
- Open Access
- 1 January 2025
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 10, 14
The current progress and futural prospects of ultrasound-targeted microbubble destruction for liver diseases: a narrative review
Background and Objective: Ultrasound (US)-targeted microbubble (MB) destruction (UTMD) involves the application of low-intensity US to MBs. This review is to illustrate the current progress and futural prospects of UTMD for liver diseases. Methods: A review of the most recent literature concerning the use of UTMD for liver diseases is presented from January 2000 to December 2023. A comprehensive search was conducted by two independent reviewers. In this review, we provide an overview of various preclinical applications of UTMD in the delivery of drugs and genes to target liver diseases, including liver cancer, liver fibrosis, and hepatic gene deficiency disorders, which have established the safety and effectiveness. Key Content and Findings: A total of 9 studies and 14 studies were identified about the preclinical applications for drug-loaded and gene-loaded UTMD for liver diseases, respectively. UTMD allows specific substances to bypass physiological barriers and reach target tissues or organs. It has been demonstrated to enhance hepatic disease drug delivery. UTMD still requires improvement in many areas, including sonographic parameters, drug-loading capacity, and range of treatable diseases. Conclusions: UTMD was shown in preclinical studies to enhance the therapeutic efficacy of drug delivery and gene therapy for liver cancer, liver fibrosis and hepatic gene defect diseases. Further clinical trials are emergent to evaluate the safety, effectiveness and long-term efficacy of UTMD in treating human liver diseases.
- 1 January 2025
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 10, 14
Open AccessThe current progress and futural prospects of ultrasound-targeted microbubble destruction for liver diseases: a narrative review
Background and Objective: Ultrasound (US)-targeted microbubble (MB) destruction (UTMD) involves the application of low-intensity US to MBs. This review is to illustrate the current progress and futural prospects of UTMD for liver diseases. Methods: A review of the most recent literature concerning the use of UTMD for liver diseases is presented from January 2000 to December 2023. A comprehensive search was conducted by two independent reviewers. In this review, we provide an overview of various preclinical applications of UTMD in the delivery of drugs and genes to target liver diseases, including liver cancer, liver fibrosis, and hepatic gene deficiency disorders, which have established the safety and effectiveness. Key Content and Findings: A total of 9 studies and 14 studies were identified about the preclinical applications for drug-loaded and gene-loaded UTMD for liver diseases, respectively. UTMD allows specific substances to bypass physiological barriers and reach target tissues or organs. It has been demonstrated to enhance hepatic disease drug delivery. UTMD still requires improvement in many areas, including sonographic parameters, drug-loading capacity, and range of treatable diseases. Conclusions: UTMD was shown in preclinical studies to enhance the therapeutic efficacy of drug delivery and gene therapy for liver cancer, liver fibrosis and hepatic gene defect diseases. Further clinical trials are emergent to evaluate the safety, effectiveness and long-term efficacy of UTMD in treating human liver diseases.
- Open Access
- 17 September 2024
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (2) , 436-442
Transjugular intrahepatic portosystemic shunt combined with dual-access thrombolysis for acute severe non-cirrhotic portal-mesenteric vein thrombosis
- 17 September 2024
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (2) , 436-442
Open AccessTransjugular intrahepatic portosystemic shunt combined with dual-access thrombolysis for acute severe non-cirrhotic portal-mesenteric vein thrombosis
- 19 January 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 76 (5) , 1232-1233
The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy
- 19 January 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 76 (5) , 1232-1233
The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy